GlassScriptPhysician profile
Stacee Sheets Goodrich
NPI 1356331409
$1,503.34
in general payments reported to CMS, 2019-2025
29 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $53.72 · 2021: $88.70 · 2022: $348 · 2023: $194 · 2024: $207 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.83 | 2019-2025 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $145.01 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $99.70 | 2022-2025 | |
| Avion Pharmaceuticals | $78.27 | 2019-2023 | Balcoltra |
| Shield Therapeutics INC | $77.96 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $68.71 | 2021-2025 | Veozah |
| Biogen, INC. | $61.72 | 2024 | Zurzuvae |
| Exeltis, USA INC. | $60.36 | 2021-2025 | Slynd |
| Vertex Pharmaceuticals Incorporated | $56.20 | 2025 | |
| Therapeuticsmd, INC. | $54.80 | 2020-2022 | |
| Evofem Biosciences, INC. | $54.48 | 2021-2024 | |
| Exact Sciences Corporation | $43.34 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $40.90 | 2023-2025 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $29.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.04 | 2025 | Trintellix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $25.52 | 2022 | |
| Hologic Sales and Service, LLC | $24.36 | 2025 | Aptima |
| Teleflex LLC | $21.26 | 2025 | Quikclot |
| Organon LLC | $21.02 | 2023 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $20.38 | 2019 | |
| Roche Diagnostics Corporation | $16.98 | 2019 | |
| Boston Scientific Corporation | $16.15 | 2025 | General - Female Sui |
| Daiichi Sankyo INC. | $16.01 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.66 | 2019 | |
| Coopersurgical, INC. | $15.60 | 2025 | Sos |
| Mission Pharmacal Company | $14.65 | 2023 | Citranatal |
| Vertical Pharmaceuticals, LLC | $12.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $10.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacee Goodrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.